Developing a Life Sciences Vision for Ireland: The EU Agenda examines how Ireland can position its national life sciences strategy in the context of the European Commission’s 2025 Strategy for European Life Sciences and other new EU initiatives. Drawing on national and EU-level experience, panellists discuss key developments in EU life sciences policy and what Europe is doing to strengthen its competitiveness, research capacity, and innovation ecosystem. The event will also explore how Ireland can secure and strengthen its own role as a key player in Europe’s life sciences landscape by aligning its policy ambitions with emerging European trends.

This event is organised by the Institute of International and European Affairs in partnership with Johnson & Johnson.

Panellists:

Pilar Aguar Fernandez, Director at People: Health and Society at DG Research and Innovation, European Commission

Anouk de Vroey, Head of Government Affairs & Policy at Johnson & Johnson EMEA

Muiris O’Connor, Assistant Secretary at Department of Health, Head of Research & Development and Health Analytics

Darrin Morrissey, CEO of NIBRT National Institute for Bioprocessing Research and Training

Frances Fitzgerald, Former MEP and Tánaiste (Moderator)

Ireland is home to a high-performing life sciences industry, offering major opportunities for both economic development and public health. Unlike other European countries, however, Ireland does not have a holistic vision for the future of the sector. This is set to change, as the Government has promised to develop a national life sciences strategy. Other European countries have already adopted ambitious strategies to secure the future of the industry and unleash its benefits, coordinating policy across a range of areas from enterprise and investment to research and healthcare.

Across the European Union, Member States are aligning national policy with broader EU ambitions for health innovation, research, and industrial resilience. Under initiatives such as Horizon Europe, the European Health Union, and EU4Health, the EU is already providing an increasingly integrated vision. In addition to this, this summer, the EU Life Sciences Strategy has been adopted by the Commission, while a new Critical Medicines Act and Biotech Act are expected soon. What will these new policies mean for Europe? And how should they be reflected in Ireland’s national strategy?